- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Alamar Biosciences, Inc. Common Stock(ALMR)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ALMR
11/13/2026: ALMR (1-star) is currently NOT-A-BUY. Pass it for now.
Alamar Biosciences is a commercial-stage life sciences company that develops ultra-sensitive proteomics platforms, including the ARGO HT System and NULISA assay kits, for early disease detection and research. The company's primary strength lies in its proprietary technology, which overcomes traditional sensitivity limitations for low-abundance protein biomarkers. Its core growth story centers on scaling instrument placements and expanding assay menus into broader clinical markets. Key risks include intense competition from established life sciences giants, ongoing operating losses, and sensitivity to research budget shifts. The stock suits growth-oriented investors willing to accept volatility in exchange for exposure to high-value proteomics innovation, with instrument adoption and menu expansion serving as key metrics to monitor.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | Alamar delivers rapid revenue expansion and high-growth potential within the emerging high-value proteomics sector. |
| Momentum investor | Strong fit while signal remains positive | The stock attracts technical interest and volatility following its high-profile public market launch. |
| Value investor | Weak fit | The company trades on forward growth expectations and does not currently focus on near-term earnings or P/E multiples. |
| Dividend investor | Weak fit | Alamar retains all capital to fund research and commercial scaling, offering no dividend yield. |
| Low-risk investor | Weak fit | As a commercial-stage life sciences equities issue, the stock experiences notable price volatility and execution risks. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Post-IPO trading dynamics and shifting sentiment in growth equities create wide stock price swings. |
| Valuation risk | Medium / high | Priced for aggressive future growth, leaving little room for operational missteps. |
| Competition risk (proteomics tools and multiplex assays) | High | Fierce competition from entrenched diagnostics giants and specialized omics players threatens market share expansion. |
| Business quality | Medium | Proprietary NULISA technology provides a strong technological moat, though commercial scaling is still maturing. |
| Dividend income | Low / none | Income-focused investors receive zero payout since all earnings are reinvested. |
| Execution risk | Medium / high | Success depends heavily on scaling instrument placements and expanding assay menus successfully into clinical markets. |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.14B USD | Price to earnings Ratio - | 1Y Target Price 37 |
Price to earnings Ratio - | 1Y Target Price 37 | ||
Volume (30-day avg) 815.1K shares | Beta - | 52 Weeks Range 17.00 - 39.61 | Updated Date 11/15/2026 |
52 Weeks Range 17.00 - 39.61 | Updated Date 11/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.13 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Medical Devices
- BUY participation
- 62.5%
- Active BUY / eligible
- 5 / 8
- 30-Day BUY Count Change
- +3
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.

Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -12.15% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Instruments | Capital sales and placements of the ARGO HT System and related automated hardware infrastructure. | Drives the installed base that subsequently locks customers into recurring consumable purchases. |
| Consumables and Assays | Recurring sales of proprietary NULISAseq and multiplex assay kits, reagents, and cartridges. | Represents the high-margin, recurring revenue engine of the business model. |
| Services and Partnerships | Fee-for-service sample testing via the Technology Access Program (TAP) and biopharma partnerships. | Builds customer familiarity and generates early-stage revenue before full instrument adoption. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1.96B | Price to Sales(TTM) 18.77 |
Enterprise Value 1.96B | Price to Sales(TTM) 18.77 | ||
Enterprise Value to Revenue 17.19 | Enterprise Value to EBITDA - | Shares Outstanding 69.48M | Shares Floating 37.75M |
Shares Outstanding 69.48M | Shares Floating 37.75M | ||
Percent Insiders 22.29 | Percent Institutions 58.91 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

